Aristine A Cheng - Infectious Diseases

Author Information

Aristine C Cheng is a researcher affiliated with the Division of Infectious Diseases at the Department of Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine in Taipei, Taiwan. Her research primarily focuses on various aspects of infectious diseases, including autoimmunity and immunopathology related to infections.

Research Contributions

Aristine C Cheng has made significant contributions to the field of infectious diseases, with a particular focus on autoimmunity and its intersection with antimicrobial immunity, as well as the immunopathology of COVID-19 in children. Her work has explored the implications of anticytokine autoantibodies and the immune responses in conditions like multisystem inflammatory syndrome in children (MIS-C) and pediatric COVID-19. Additionally, she has investigated the impact of low-level viremia in HIV patients and the efficacy of antiretroviral therapies. Cheng's research also extends to innovative treatments for chemical burns and their associated infections, demonstrating a broad range of interests in her field.

Aliases

Aristine C Cheng is also known by several aliases, including A Cheng, Aris Cheng, Aristine A Cheng, and Aristine Cheng. These variations might appear in different publications or databases, but they all refer to the same researcher.

Publication and Citation Metrics

Metric	Value
Total Citation Count	2105
H-index	26
Total Paper Count	115

Publications:

Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity

DOI: 10.1016/j.jaci.2021.11.016

Year: 2022

Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19.

DOI: 10.1038/s41591-022-01724-3

Year: 2022

BCG-infection in patients with Inborn Errors of Immunity receiving the Russian BCG-strain.

DOI: 10.1016/j.jaip.2022.03.032

Year: 2022

Neutralizing GM-CSF autoantibodies in pulmonary alveolar proteinosis, cryptococcal meningitis and severe nocardiosis

DOI: 10.21203/rs.3.rs-1344301/v1

Year: 2022

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.

DOI: 10.1016/j.ijid.2021.02.045

Year: 2021

Temporal Dynamics of Anti-Type 1 Interferon Autoantibodies in COVID-19 Patients

DOI: 10.1093/cid/ciab1002

Year: 2021

Chitosan-based hydrogels to treat hydrofluoric acid burns and prevent infection.

DOI: 10.1007/s13346-021-01007-3

Year: 2021

Correction to: Chitosan‑based hydrogels to treat hydrofluoric acid burns and prevent infection

DOI: 10.1007/s13346-021-01098-y

Year: 2021

Multi-omics approach identifies novel age-, time- and treatment-related immunopathological signatures in MIS-C and pediatric COVID-19

DOI: 10.1101/2021.09.24.21263853

Year: 2021

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study

DOI: 10.1007/s40121-021-00424-8

Year: 2021

What are the Challenges in Studying Parasite DNA?

What is Pathogenesis?

What Are Functional Assays?

What Are the Key Components of a One Health Approach?

What is the Role of Public Health in Managing Infectious Diseases?

How Do RDTs Work?

How Can Measles be Prevented?

What Are the Latest Advances in Immunotherapy?

How Can We Combat Antibiotic Resistance?

How Can Education Help in the Prevention of Infectious Diseases?

Partnered Content Networks

Relevant Topics